Selling, General, and Administrative Costs: Walgreens Boots Alliance, Inc. vs Novavax, Inc.

A Tale of Two Companies: Walgreens Boots Alliance vs. Novavax

In the ever-evolving landscape of corporate finance, Selling, General, and Administrative (SG&A) expenses serve as a critical indicator of a company's operational efficiency. From 2014 to 2023, Walgreens Boots Alliance, Inc. consistently outpaced Novavax, Inc. in SG&A expenditures, reflecting its expansive global operations. Walgreens' SG&A costs hovered around $23 billion annually, peaking at $28 billion in 2024, showcasing a steady growth trajectory. In contrast, Novavax's expenses surged by over 2,300% from 2014 to 2023, reaching nearly $489 million, indicative of its aggressive expansion and R&D investments. This stark contrast highlights the differing scales and strategies of these two industry players. While Walgreens' expenses reflect its established market presence, Novavax's rising costs underscore its rapid growth ambitions. Notably, 2024 data for Novavax is missing, leaving room for speculation on its future financial strategies.